Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea
This study will recruit 66 patients with obstructive sleep apnea, comprising 33 men and 33 women, who have been referred to the sleep center by their doctors for polysomnograms (PSG). The subjects will undergo two overnight sleep PSG sessions at the sleep center. The interval between the two examinations will be at least 7 days, during which they will receive both a placebo and medication conditions, administered 1 hour before bedtime. The study drugs will include: (1) atomoxetine 80 mg and oxybutynin 5 mg; or (2) venlafaxine 37.5 mg; or (3) atomoxetine 80 mg and trazodone 100 mg. Endotypic traits will be estimated using the Phenotyping Using Polysomnography method. The primary outcome is the change in apnea-hypopnea index, and secondary outcomes include endotypic traits and sleep parameters.
- EligibilityCriteria: Inclusion Criteria:  apnea-hypopnea index ≥ 15 hr-¹  Exclusion Criteria:  the presence of pulmonary, cardiac, neurologic, or other active severe medical or psychiatric diseases current use of continuous positive airway pressure therapy use of drugs that might interact with the investigational medication or known to affect sleep during the trial or 1 month before the study known allergy to the investigational medication current smoking heavy alcohol drinking (male > 14 drinks and women >7 drinks per week) pregnant or lactating periodic limb movement index ≤ 15hr-1 the presence of sleep-related hypoventilation - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - StdAgeList: Adult, Older Adult